XML 68 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation (Stock Appreciation Rights Activity) (Details)
6 Months Ended
Jul. 31, 2021
USD ($)
$ / shares
shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ $ 1,020,000
Stock Appreciation Rights Activity, Number of Underlying Shares  
Number of Underlying Shares, Beginning Balance at January 30, 2021 | shares 384,757
Number of Underlying Shares, Granted | shares 0
Number of Underlying Shares, Exercised | shares (107,068)
Number of Underlying Shares, Forfeited | shares (34,150)
Number of Underlying Shares, Ending Balance at July 31, 2021 | shares 243,539
Number of Underlying shares, Stock appreciation rights exercisable | shares 243,539
Number of Underlying Shares, Stock appreciation rights expected to become exercisable | shares 0
Stock Appreciation Rights, Weighted-Average Exercise Price  
Weighted-Average Grant Date Fair Value, Beginning Balance at January 30, 2021 | $ / shares $ 33.04
Weighted-Average Exercise Price, Granted | $ / shares 0
Weighted-Average Exercise Price, Exercised | $ / shares 26.89
Weighted-Average Exercise Price, Forfeited or expired | $ / shares 54.87
Weighted-Average Grant Date Fair Value, Ending Balance at July 31, 2021 | $ / shares 32.69
Weighted-Average Exercise Price, Stock appreciation rights exercisable | $ / shares 32.69
Weighted-Average Exercise Price, Stock appreciation rights expected to become exercisable | $ / shares $ 0
Aggregate Intrinsic Value, Outstanding | $ $ 2,029,216
Aggregate Intrinsic Value, Stock appreciation rights exercisable | $ 2,029,216
Aggregate Intrinsic Value, Stock appreciation rights expected to become exercisable | $ $ 0
Weighted-Average Remaining Contractual Life, Outstanding 2 years 9 months 18 days
Weighted-Average Remaining Contractual Life, Stock appreciation rights exercisable 2 years 9 months 18 days
Weighted Average Remaining Contractual Life, Stock appreciation rights expected to become exercisable 0 years